Skip to main content

Table 3 Toxicity after Celltop® and radiation

From: Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004–02

  25 mg/day 50 mg/day
Mucositis   
Grade 1/2   3
Grade 3 3 7
Radiodermitis   
Grade 1/2 3 6
Grade 3   4
Dysphagia   
Grade 1/2 3 6
Grade 3   4
Leucopenia   
Grade 1/2 1 1
Grade 3/4   2
Neutropenia   
Grade 1/2   1
Grade 3/4   2
Thrombopenia   
Grade 1/2   1
Anemia   6
Grade 1/2   
Renal   2
Grade 1